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Gleason scoreThe aim of this study was to investigate the expression of a panel of integrins in prostate cancer in order to
explore their potential for tumor biology. Formalin-ﬁxed and parafﬁn-embedded tissue samples of 1284 prostate
cancer patients were retrieved from the archive of the Department of Pathology. Immunostainingwas donewith
rabbit monoclonal antibodies directed against αvβ3, αvβ5, αvβ6, αvβ8, β3, and αv-pan. Staining results were
correlated with clinicopathologic patient characteristics and patient survival. Immunostaining of tumor cells
performed on whole tissue sections of 52 patients was sparse for αvβ3, αvβ6, and αvβ8, and more prevalent
for αvβ5 and αv-pan. αvβ5, αvβ8, and αv-pan were selected for further analyses in tissue microarrays
representing the entire study cohort. αvβ8 staining was generally observed in peripheral nerves. αvβ5
and αv-pan provided strong evidence for the differential expression of these integrins in prostate cancer.
The expression was variable with regard to the histoanatomical/cytoanatomical localization, cell type, intensity
of immunolabeling, and Gleason pattern. αvβ5 and αv-pan are differentially expressed in prostate cancer, and
the differentiation of prostate cancer seems to inﬂuence integrin expression and subcellular distribution.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Prostate cancer is the second most common cancer in men and
the sixth most common cause of cancer death in the world [1,2]. The
most important factors affecting patient outcome are tumor stage,
tumor grade according to the Gleason Score (GS) and serum levels of
prostate-speciﬁc antigen [3].
Recently, several markers like galectin 3, circulating microRNAs, and
integrins were discussed as new prognostic biomarkers [4–7]. Integrins
are transmembrane receptors that mediate cell signaling pathways.
Because of their various physiological functions in cell survival and
differentiation, they play important roles in the pathology of tumor
progression and metastasis [8,9]. During the last decades, systematic
investigations have been hampered by the lack of antibodies suitable for
formalin-ﬁxed and parafﬁn-embedded (FFPE) tissue, and current knowl-
edge about integrins is mainly derived from cell line analyses [10].
Lately, integrins, particularlyαvβ3 andαvβ5, becameputative novel
targets for the treatment of several cancer entities, which has spurred
research on integrins in cancer biology [11]. For this reason, the charac-
terization of integrin distribution in human tumors is of great interest.
Among the integrins, αvβ3 and αvβ5 are expressed among others inhristian-Albrechts-University,
y. Tel.: +49 431 597 3401;
).
. This is an open access article underendothelial cells and promote cell survival [12]. They play an important
role in angiogenesis, which is essential for tumor progression and
metastasis [13]. In bone metastasis, αvβ3 is responsible for bone
turnover in the interaction with osteopontin [14].
αvβ6 and αvβ8, in turn, interact with TGF-β and play an important
role in the immune response. αvβ6 inﬂuences regulatory T cells and
seems to be involved in the avoidance of immune reaction in colorectal
cancer, which promotes tumor spread [15,16]. αvβ8 has a key part
in the blood vessel development during embryogenesis and is expressed
in several human tumors [17]. Moreover, the up-regulation of some
integrin subunits in prostate cancer has beenpreviously described [18,19].
The aim of this study was to investigate the expression of a panel of
integrins (αvβ3, αvβ5, αvβ6, αvβ8, β3, αv-pan) in prostate cancer in
order to explore their potential signiﬁcance for tumor biology. For this
purpose, a large retrospective cohort of prostate cancer specimens
was retrieved and immunohistochemistry was applied using newly
established rabbit monoclonal integrin antibodies that have previously
been shown to react speciﬁcally in FFPE tissue. Results of immunostain-
ing were correlated with clinicopathologic patient characteristics.
2. Material and methods
2.1. Ethics statement
This project was approved by the local ethics committee of the
University Hospital in Kiel, Germany (AZ 110/99). All patient data
were pseudonymized before study inclusion.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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From the archive of the Department of Pathology, Christian-
Albrechts-University Kiel, we retrieved all cases that had undergone
radical prostatectomy for prostate cancer spanning the period from
1997 to 2011. All specimens had been ﬁxed in formalin, embedded in
parafﬁn (FFPE), and stored at room temperature. Study inclusion crite-
rion was prostatectomy with histologically conﬁrmed prostate cancer.
Patients were excluded if clinical data were incomplete and prostate
cancer featured less than 10% of tissue samples or offered retraction
artifacts of the tumor glands due to autolysis. Biopsy samples and
transurethral resection specimens were excluded. Date and cause of
patient death were obtained from the Epidemiological Cancer Registry
of the state of Schleswig-Holstein, Germany. Follow-up data of patients
who are still alive were retrieved from hospital records.
2.3. Histology
De-parafﬁnized tissue sections were stained with hematoxylin and
eosin. Tumor stage was reclassiﬁed according to the seventh edition of
the TNM classiﬁcation of the Union internationale contre le cancer
(UICC). Tumor type and histologic grading were classiﬁed according to
the World Health Organization classiﬁcation of prostate cancer
and the revised Gleason grading system [20,21]. The Gleason grading
was separately applied to whole tissue sections (WTS) and tissue
microarrays (TMA).
2.4. Tissue microarray construction
Formalin-ﬁxed and parafﬁn-embedded tissue samples were used to
generate TMAs as described previously [22]. Brieﬂy, 3 morphologically
representative regions of a single parafﬁn “donor” block were chosen
per cancer sample. Tissue cylinders of 1.5-mm diameter were punched
from these areas, precisely arrayed into a new “recipient” parafﬁn block
using a custom-built instrument (Beecher Instruments, Silver Spring,
Maryland). Serial sections of 2.5 μmwere cut for further analysis.
2.5. Immunohistochemistry
Immunohistochemical stainings were performed with a Ventana
Benchmark ULTRA (Roche Diagnostics, Mannheim, Germany), using
the ULTRAView Universal DAB Kit (Roche Diagnostics). Formalin-ﬁxed
and parafﬁn-embedded material from each tumor was stained with 6
recently established monoclonal rabbit antibodies (Table 1) directed
against integrin complexes or individual chains, as previously described
[23]. The biochemical speciﬁcity of the antibodies against integrins,
which were used in this study, has been precisely deﬁned [24,25].
They detect the αvβ3 (EM22703), αvβ5 (EM09902), αvβ6 (EM052),
and αvβ8 (EM13309) heterodimeric complexes; the αv chain in all
the αv heterodimeric complexes (EM01309); or the β3 chain cytoplas-
mic domain (EM00212).
2.6. Study design
To evaluate the immunostaining characteristics of the different anti-
bodies with regard to the staining pattern and intensity, a test cohort ofTable 1
Staining protocols
Antigen Clone Source Pr
αvβ3 EM22703 Merck, Darmstadt, Germany Pr
αvβ5 EM09902 Merck Pr
β3 EM00212 Merck CC
αvβ6 EM05201 Merck Pr
αvβ8 EM13309 Merck Pr
αv-pan EM01309 Merck CC52 samples, represented on WTS, was set up from the entire cohort,
which represented in equal amounts the different GS of prostate cancer.
For those antibodies that showed no positive staining results in WTS, a
cohort of 112 cases, represented on TMAs, was stained to see if the pri-
mary staining resultswere conﬁrmed. For those antibodies that showed
positive staining results on theWTS, stainingwas performed for the en-
tire cohort using TMAs. Staining results were correlated among them-
selves and with clinicopathologic data.
2.7. Read-outs
The quantity, intensity, and localization of immunoreactivity within
the tumor cells were assessed for each antibody. Localization of immu-
noreactivity was evaluated as (1) membranous linear intercellular
staining, (2) basal staining localized at the interface between tumor
cell complexes and stroma, and/or (3) cytoplasmic staining.
Immunostaining was evaluated using the HistoScore (Hscore) as
previously described [26]. The ﬁrst parameter was based on the intensity
of the stained cells. A score of 0 (no evidence of staining) to 3 (strong
staining reaction) was applied. The second parameter (P) estimates the
distribution of the stained cells in percentage. Finally, an Hscore was cal-
culated according to the following formula:HScore=(0× P)+ (1× P)+
(2 × P) + (3 × P), resulting in an Hscore ranging from 0 to 300.
Moreover, an optional integrin expression in other tumor components
than cancer cells (eg, perineural sheets andnonneoplastic prostate tissue)
was documented as side notes, but not systematically analyzed.
2.8. Statistical analysis
The statistical analysiswas performedwith SPSS Statistics 18.0 (SPSS
Institute, Chicago, Illinois). Fisher exact test, Kendall τ, and log-rank test
were used to correlate the integrin expression with clinicopathologic
patient characteristics as well as for the comparison of WTS with the
corresponding TMA staining results. Survival data of the patients were
illustrated by Kaplan-Meier curves and compared using the log-rank
test. Every test was rated by the P value. A P value less than .05 was
considered statistically signiﬁcant.
3. Results
3.1. Study population
A total of 1284 male patients fulﬁlled all study inclusion criteria
(Table 2). In 1272 cases (99.1%), a GS could be evaluated. The GS repre-
sented the major prognostic factor. Follow-up period ranged from 0.03
to 189.5 months (mean [SD], 70.7 [41.7]).
3.2. Expression of integrins in prostate cancer
Because of the rather low expression of integrinαvβ3,β3,αvβ6, and
αvβ8 in prostate cancer cells in a test cohort of 52 WTS, evaluation of
the entire cohort was neglected for these antibodies. Only 112 tumor
samples, represented on TMAs, were evaluated to see if the primary
staining results found in WTS were conﬁrmed.
αvβ5 and αv-pan showed a distinctive immunoreaction in prostate
cancer cells, and subsequently, the entire cohort was studied using TMAs.etreatment Antibody dilution Detection system
otease 2 1:100 Ventana Benchmark ULTRA
otease 2 1:5000 Ventana Benchmark ULTRA
1 1:80 Ventana Benchmark ULTRA
otease 2 1:1000 Ventana Benchmark ULTRA
otease 2 1:500 Ventana Benchmark ULTRA
1 1:20.000 Ventana Benchmark ULTRA
Table 2
Clinicopathologic patient characteristics
Parameter n (% of valid)
Patient no. 1284
Age (y), mean ± SD 65.1 ± 6.2
Follow-up data 1255
Alive 1101 (87.7)
Dead 154 (12.3)
Prostate-speciﬁc death 24 (1.9)
Local tumor growth
T2aa 161 (12.6)
T2b 90 (7.2)
T2c 568 (44.4)
T3a 254 (19.8)
T3b 186 (14.5)
T4 19 (1.5)
Lymph node metastases
N0 1098 (89.1)
N1 135 (10.9)
Distant metastases
M0 5 (55.6)
M1 4 (44.4)
UICC tumor stage
I 147 (11.6)
II 642 (50.5)
III 335 (26.3)
IV 148 (11.6)
Lymphatic vessel invasion
L0 800 (89.9)
L1 90 (10.1)
Blood vessel invasion
V0 904 (98.0)
V1 18 (2)
Perineural invasion
Pn0 67 (12.6)
Pn1 466 (87.4)
Resection margin
R0 967 (77.7)
R1/R2 277 (22.2)
Tumor grade
G1 21 (1.6)
G2 818 (64)
G3 440 (34.4)
GS
6 427 (33.6)
7 (low risk)b 425 (33.4)
7 (high risk)b 186 (14.6)
8 122 (9.6)
9 106 (8.3)
10 6 (0.5)
Gleason 7 high-risk group contains all cases with a GP4 + 3 and 5 + 2.
a T1a and T1b were summarized to T2a, diagnosed at the prostatectomy specimen.
b Gleason 7 low-risk group contains all cases with a GP3 + 4 and 2 + 5.
Table 3
Distribution of expression ofαvβ3,αvβ6, andαvβ8 inprostate cancer cells, separated into
basal, cytoplasmic, and membranous staining (mean ± SD)
Tumor cells Integrins
αvβ3 αvβ6 αvβ8
WTSs n (missing) 52 (1) 52 (2) 52 (0)
Basal 0 ± 0 12.1 ± 29.0 0 ± 0
Cytoplasmic 7.8 ± 36.9 4.7 ± 24.0 2.1 ± 6.3
Membranous 0 ± 0 0 ± 0 0 ± 0
TMAs n (missing) 112 (0) 112 (1) 1211 (0)
Basal 0 ± 0 6.8 ± 29.6 0 ± 0
Cytoplasmic 0.09 ± 0.95 8.3 ± 31.5 1.7 ± 11.7
Membranous 0 ± 0 5.1 ± 22.8 0.01 ± 0.29
Nontumor cells Integrins
αvβ3 αvβ8
WTSs n (missing) 52 (1) 52 (0)
Blood vessels 138.0 ± 95.0
Perineural sheaths 112.0 ± 85.0
TMAs n (missing) 112 (0) 691 (520)
Blood vessels 75.5 ± 83.0
Perineural sheaths 192.0 ± 140.0
In addition, the integrins αvβ3 and αvβ8 were found in intratumoral blood vessels and
perineural sheaths, respectively (mean ± SD).
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In WTS obtained from 51 patients (1 missing value), most tumor
cells were immunonegative for αvβ3. Subsequently, TMA samples ob-
tained from 112 separate patients were immunohistochemically
stained, and ﬁndings made in WTS were conﬁrmed (Table 3).
3.2.2. β3 integrin
β3 was not expressed by prostate cancer cells either in WTS or in
TMAs, but β3 expression was found in extratumoral blood vessel walls
of 48 (94.1%) of 51 patients (WTS) and in 19 (17.3%) of 110 patients
(TMAs), respectively.
3.2.3. αvß6 integrin
Ten cases showed a basal immunostaining and 3 cases showed a
cytoplasmic immunostaining of the tumor cells in WTS (Table 3).
Moreover, the stratiﬁed epithelium of excretory ducts showed a mainly
strong immunolabeling. All other tumor components (eg, tumor stroma
and blood vessels) were immunonegative.Because of the predominantly weak staining of tumor cells, only 111
patients (1 missing value) were evaluated on TMAs. Previous ﬁndings
were conﬁrmed (Table 3).
3.2.4. αvß8 integrin
The anti-αvβ8 antibody showed a strong immunostaining of peri-
neural sheaths (Pn) with and without tumor cell inﬁltration. The 52
WTS demonstrated that the tumor cells were mainly immunonegative,
as well as the prostatic stroma (Table 3). The nonneoplastic glands
showed a weak immunoreaction in 25 (50%) patients.
3.2.5. αvß5 and αv-pan integrins
Most tumor cells, stroma cells, and nonneoplastic glands showed a
positive immunoreaction for both αvβ5 and αv-pan in WTS. The basal
cells of nonneoplastic glands constantly showed a mainly strong
immunolabeling. Hence, the expression of αvβ5 and αv-pan was eval-
uated for WTS (52 cases) as well as for the entire cohort (1255 cases)
using TMAs. Staining results of αvβ5 and αv-pan were correlated
with the Gleason pattern (GP), clinicopathologic patient characteristics,
and survival.
3.2.5.1. Evaluation of αvβ5 and αv-pan expression in WTSs.αvβ5 showed
a predominantly weak basal immunoreaction in tumor cells. The
cytoplasmic and membranous expression increased with an advanced
GP (Fig. 1; Table 4).
Basal expression of αv-pan increased with advanced GP. Cytoplas-
mic immmunostaining of αv-pan was usually weak with no signiﬁcant
differences between the different GPs. Membranous immunostaining
decreased from GP3 to GP5 (Fig. 2; Table 4).
3.2.5.2. Evaluation of αvβ5 and αv-pan expression in TMAs. Both antibod-
ies showed a basal, cytoplasmic, and membranous staining of tumor
cells. Because of the different growth patterns and the loss of cellular
structure of GP4 and GP5, the membranous and basal staining of αv-
pan was not detectable in every patient (Table 4).
As shown in Table 5, GP4 and GP5 showed different staining results
depending on the different phenotypes (fusiform, cribriform, ill-
deﬁned, papillary, mucinous, and solid with necrosis). The basal layer
of the cribriform glands and the solid tumor nestswith necrosis showed
the strongest immunoreaction with both antibodies.
Fig. 1. Expression of αvβ5 in prostate cancer. This ﬁgures illustrates prostate carcinoma with a GP3 with strong basal and moderate cytoplasmic expression of αvβ5 (A), GP4 cribriform
growth pattern (B), GP4 with ill-deﬁned glands and small gland fusion (C), and GP5 solid with comedonecrosis (D). Original magniﬁcation 200-fold.
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characteristics. Membranous immunostaining of αv-pan correlated
signiﬁcantly inversely with the GP. Moreover, cytoplasmic αvβ5
expression correlated signiﬁcantly with the GP and with the tumor
grade (Table 6).
There was no correlation with any other clinicopathologic
patient characteristic.
3.2.5.4. Correlation between immunostaining of αvβ5 and αv-pan.
As shown in Table 7, signiﬁcant coincidental expression was found for
basal, cytoplasmic, and membranous immunostaining of αvβ5 and
αv-pan, respectively.
3.3. Survival analyses
One hundred ﬁfty-four patients (12.0%) died during the study peri-
od. Twenty-four (1.9%) patients died of prostate cancer, 106 (8.3%) of
other diseases, and 24 (1.9%) of unknown reason. Correlation betweenTable 4
Distribution of expression of αvβ5 and αv-pan in prostate cancer cells, separated into basal, cy
GP αv-pan WTS Hscore αv-pan TMA Hscore
n Mean n Mean
Basal 3 23 69.0 ± 59.0 P= .207;
τ= 0.172
707 62.0 ± 55.0 P=
τ=
4 14 89.0 ± 75.0 286 75.0 ± 65.0
5 2 120.0 ± 0 34 74.0 ± 76.0
Cytoplasmic 3 23 91.0 ± 69.0 P= .591;
τ=−0.062
706 62.0 ± 55.0 P=
τ=
4 16 69.0 ± 40.0 366 70.0 ± 55.0
5 11 94.0 ± 83.0 103 71.0 ± 58.0
Membranous 3 23 27.0 ± 46.0 P= .880;
τ=−0.022
704 40.0 ± 46.0 P=
τ=
4 14 24.0 ± 36.0 289 33.0 ± 45.0
5 2 2.5 ± 3.5 35 26.0 ± 42.0clinicopathologic patient characteristics and overall survival or tumor-
speciﬁc survival is illustrated in Table 8.
Because of the small number of cancer-related deaths, it was impos-
sible to analyze prostate cancer–speciﬁc patient survival using the
Kaplan-Meier curves, although the log-rank test revealed a signiﬁcant
correlation between tumor-speciﬁc survival and basal expression of
αvβ5 as well as overall survival with αvβ5 membranous expression.
4. Discussion
This study was designed to investigate integrin expression in pros-
tate cancer. Integrins belong to a family of heterodimeric cell surface re-
ceptors and interact through an RGD binding domain with extracelluar
ligands [27].Within their function to facilitate cell survival and differen-
tiation, they play an important role in tumor progression andmetastasis
[13,10]. Ideas about pharmacologic treatment based on the inhibition of
integrins already exist; therefore, a veriﬁcation of integrin expression in
different tumors would be preferable.toplasmic, and membranous staining
αvβ5 WTS Hscore αvβ5 TMA Hscore
n Mean n Mean
.002;
0.080
23 88.0 ± 80.0 P= .604;
τ= 0.059
733 64.0 ± 57.0 P= .772;
τ= 0.008
16 96.0 ± 54.0 293 73.0 ± 71.0
11 85.0 ± 47.0 35 62.0 ± 68.0
.003;
0.073
23 92.0 ± 62.0 P= .962;
τ=−0.007
732 49.0 ± 54.0 P b .001;
τ= 0.089
14 79.0 ± 67.0 374 62.0 ± 63.0
3 117.0 ± 78.0 108 61.0 ± 62.0
.001;
−0.092
23 8.7 ± 23.0 P= .429;
τ= 0.118
728 11.0 ± 32.0 P= .881;
τ=−0.004
14 11.0 ± 26.0 290 12.0 ± 35.0
4 32.0 ± 47.0 34 1.5 ± 4.4
Fig. 2. Expression of αv-pan in prostate cancer. This ﬁgure illustrates prostate carcinoma with a GP3 with strong basal andmoderate cytoplasmic expression of αvβ5 (A), GP4 cribriform
growth pattern (B), GP4 with ill-deﬁned glands and small gland fusion (C), and GP5 solid with comedonecrosis (D). Original magniﬁcation 200-fold.
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lack of antibodies suitable for FFPE tissue. We report the ﬁrst extensive
longitudinal investigation of the expression of the main αv
integrins in a cohort of prostate cancer, using novel rabbit monoclonal
antibodies suitable for FFPE tissue. In addition, putative prognostic
patient characteristics such as GS and TNM status were compared
with patient survival.
One of the most interesting ﬁndings was the variability of the ex-
pression of all investigated markers. In our study, αvβ3 was expressed
in blood vessels as previously described [25]. αvβ3 is known to be an
important factor of tumor progression and metastasis in prostate can-
cer, although the direct expression by tumor cells in prostate was not
conﬁrmed. Therefore, it is plausible to speculate that αvβ3 may be in-
volved in bone metastases despite an absent extensive expression in
prostate cancer cells [28]. β3 showed no expression in intratumoral
blood vessels, but in peripheral extratumoral blood vessels near the
prostate capsule. Because of the different staining results in blood ves-
sels, β3 offers the possibility to differentiate between nonneoplastic
and tumor-associated blood vessels.Table 5
Correlation of the αv-pan and αvβ5 integrin expression with the different growth patterns of
Growth pattern Hscore αv-pan
n % of valid Basal,
mean ± SD
Cytoplasmic,
mean ± SD
M
m
GP4 Small gland fusion 82 17.4 – 70.0 ± 54.0 0
Cribriform 182 38.7 91.0 ± 69.0 76.0 ± 56.0 3
Ill-deﬁned glands 99 21.2 49.0 ± 45.0 62.0 ± 54.0 2
Papillary 1 0.2 20.0 20.0 0
Mucinous 3 0.6 43.0 ± 51.0 0 3
GP5 Solid with comedonecrosis 7 1.5 127.0 ± 62.0 73.0 ± 40.0 1
Fusion/Solid sheets 69 14.7 0 72.0 ± 56.0 0
Cribriform/papillary
without necrosis
27 5.7 63.0 ± 74.0 68.0 ± 67.0 3
Total 470 100.0In most of our cases, anti-αvβ6 immunostained the basal layer of
benign glands without staining tumor cells or stroma cells. Anti-αvβ8
showed a strong staining of peripheral nerve sheaths or neural axons,
but did not correlate with any of the tested parameters. Thus, the ex-
pression of αvβ6 and αvβ8 does not seem to be tumor biologically rel-
evant in the primary prostate cancer.
Among the integrins studied herein, onlyαvβ5 andαv-pan were al-
most ubiquitously expressed in prostate cancer cells, and their expres-
sion varied with regard to histopathologic localization. To date, only
little is known about the biological signiﬁcance of αvβ5 and αv-pan in
prostate carcinoma, asmost of the previous studies focused onαvβ3 in-
stead. In cell culture studies, an enhanced expression ofαvβ3 andαvβ5
resulted in amore spreadmorphology and in a survival advantage of the
cells in culture via a delay of apoptosis [29]. Another study describes
that αv and αvβ5, respectively, show a similar expression pattern in
cells isolated from either prostate carcinomaor normal tissue, and espe-
cially, αvβ5 was found to be poorly expressed [30]. Moreover, αv
integrins, including αvβ3 and αvβ5, are known to promote survival of
prostate cancer cells in bonemetastasis via adherence to and migrationGleason grades 4 and 5
Hscore αvβ5
embranous,
ean ± SD
n % of valid Basal, mean ± SD Cytoplasmic,
mean ± SD
Membranous,
mean ± SD
± 0 82 16.9 – 57.0 ± 54.0 0
6.0 ± 49.0 185 38.1 96.0 ± 74.0 71.0 ± 69.0 15.0 ± 41.0
8.0 ± 38.0 105 21.6 34.0 ± 42.0 50.0 ± 58.0 6.0 ± 17.0
1 0.2 20.0 60.0 0
7.0 ± 55.0 4 0.8 30.0 ± 48.0 25.0 ± 50.0 0
4.0 ± 38.0 7 1.4 84.0 ± 69.0 23.0 ± 36.0 0
73 15.1 – 62.0 ± 57.0 –
0.0 ± 44.0 28 5.8 57.0 ± 68.0 69.0 ± 77.0 2.0 ± 5.0
485 100.0
Table 6
Expression of αvβ5 and αv-pan in prostate cancer cells compared with clinicopathologic patient characteristics investigated in TMAs
αvβ5 TMA αv-pan TMA
Basal, n (%)(m) Cytoplasmic, n (%)(z) Membranous, n (%)(m) Basal, n (%)(m) Cytoplasmic, n (%)(z) Membranous, n (%)(m)
T category n p(2) .130 .685 .795 .169 .579 .721
T2a 61 (50.4) 77 (57.5) 23 (19.2) 62 (52.1) 69 (53.1) 57 (47.9)
T2b 45 (63.4) 58 (70.7) 16 (22.5) 36 (54.5) 41 (53.9) 34 (50.7)
T2c 235 (49.6) 321 (62.3) 63 (13.4) 230 (49.6) 231 (45.8) 256 (55.5)
T3a 105 (50.5) 145 (61.4) 42 (20.4) 92 (47.4) 116 (52.0) 100 (51.0)
T3b 56 (45.9) 110 (64.0) 20 (16.7) 53 (44.5) 76 (45.8) 64 (53.3)
T4 4 (30.8) 12 (70.6) 3 (23.1) 6 (54.5) 8 (53.3) 6 (54.5)
N category n p(1) 1.000 .846 .100 .827 .568 .442
N0 439 (50.0) 620 (62.8) 149 (17.1) 414 (49.1) 457 (48.2) 448 (53.1)
N1 47 (50.5) 81 (63.8) 9 (9.9) 44 (47.8) 64 (51.2) 53 (57.6)
UICC stage n p(2) .612 .441 .024(1) .198 .950 .826
I 55 (49.5) 69 (56.6) 22 (20.0) 58 (53.2) 63 (53.4) 51 (46.8)
II 272 (51.2) 367 (63.5) 78 (14.8) 257 (49.9) 264 (47.1) 284 (55.4)
III 124 (48.8) 196 (63.2) 55 (21.8) 109 (45.6) 144 (49.0) 121 (50.0)
IV 50 (48.5) 87 (63.0) 11 (10.9) 48 (48.0) 67 (50.0) 56 (56.0)
Lymphatic invasion n p(1) .700 .402 .358 .148 1.000 .507
L0 327 (52.6) 459 (64.5) 86 (14.0) 322 (52.5) 342 (48.9) 354 (58.0)
L1 33 (50.0) 60 (69.8) 12 (18.2) 27 (42.2) 41 (49.4) 34 (53.1)
Venous invasion n p(1) .755 .198 .166 .753 .620 1.000
V0 370 (52.2) 529 (65.1) 100 (14.3) 359 (51.4) 390 (48.9) 404 (58.1)
V1 6 (60.0) 14 (82.4) 3 (30.0) 6 (60.0) 9 (56.2) 6 (60.0)
Perineural invasion n p(1) .566 .486 .539 .775 .787 .064
Pn0 30 (52.6) 36 (58.1) 6 (10.7) 26 (45.6) 31 (50.0) 35 (61.4)
Pn1 207 (57.2) 267 (62.8) 53 (15.0) 172 (48.6) 199 (48.1) 169 (47.7)
Resection status n p(2) .274 .674 .470 .204 .886 .352
R0 388 (51.0) 536 (62.5) 131 (17.3) 363 (49.7) 400 (48.6) 380 (52.1)
R1 100 (46.7) 168 (63.9) 32 (15.2) 93 (44.5) 127 (49.4) 118 (55.9)
R2 0 (0) 1 (100.0) 0 (0) 0 (0) 0 (0.0) 0 (0)
Gleason n p(2) .713 .001 .901 .342 .575 b.001
3 346 (49.6) 411 (58.9) 116 (16.7) 321 (48.0) 328 (49.1) 379 (56.9)
4 146 (52.5) 241 (67.3) 47 (17.1) 145 (53.1) 170 (48.3) 128 (46.4)
5 14 (41.2) 73 (70.9) 4 (12.1) 13 (40.6) 44 (45.4) 11 (33.3)
p(1), P value of Fisher exact test; p(2), P value of Kendall τ test; (z), dichotomized at zero (Hscore=0: negative; Hscore N 0: positive); (m), dichotomized at themedian (Hscore bmedian:
negative; score Nmedian: positive); nc, cannot be calculated.
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scribed regarding the localization ofαvβ5 andαv-pan immunostaining
and its signiﬁcance in prostate carcinoma. In the present study, mem-
branous immunostaining of αv-pan correlated signiﬁcantly inversely
with the GP. Moreover, cytoplasmic immunostaining of tumor cells
with anti-αvβ5 correlated signiﬁcantly with the GP. Thus, the differen-
tiation of prostate cancermay inﬂuence integrin expression and subcel-
lular distribution, for example, via integrin trafﬁcking [33]. GP4 andGP5,
as a result of ill-deﬁned glands, lose their membranous cell borders.
Consequently, the number of tumors with positive membranous
staining and the intensity of immunostaining decreased. These results
appear to be partly contradictory to former ﬁndings that say that an in-
creased αvβ5 expression comes along with a more aggressive tumor
behavior, as it is known to be on hand for tumors with a GP4 or GP5.Table 7
Correlation of αvβ5 and αv-pan integrin expression in prostate cancer
αv-pan αvβ5 TMA
Basal(m)
Negative, n (%) Positive, n (%)
Basal n p(1) 960 b.001
Negative 333 (68.5) 153 (31.5)
Positive 139 (29.3) 335 (70.7)
Cytoplasmic n p(1)
Negative
Positive
Membranous n p(1)
Negative
Positive
p(1), P value of Fisher exact test; (z), dichotomized at zero (Hscore= 0: negative; Hscore N 0: p
positive.Nevertheless, processes like trafﬁcking could inﬂuence the subcellular
distribution of the immunostaining: it might be conceivable that in ill-
deﬁned glands, the integrin heterodimers got endocytosed from
the plasma membrane in to the cytoplasm; this mechanism could be a
possible explanation for the change from membranous to cytoplasmic
immunostaining within ill-deﬁned glands. However, further investiga-
tions in this interesting ﬁeld of cancer research are needed. However,
our observations lead to the conjecture that integrin expression
may also serve as a novel immunohistochemical marker of tumor
cell differentiation.
Because both integrins are closely tied to the GS, αv-pan and αvβ5
are no independent prognostic markers. The cancer-speciﬁc biological
relevance is unknown and, in this case, not measurable. The expression
of αvβ5 in the basal cell compartment and its correlation with tumor-αvβ5 TMA αvβ5 TMA
Cytoplasmic(z) Membranous(m)
Negative, n (%) Positive, n (%) Negative, n (%) Positive, n (%)
1104 b.001
293 (51.5) 276 (48.5)
108 (20.2) 427 (79.8)
950 b.001
411 (93.2) 30 (6.8)
378 (74.3) 131 (25.7)
ositive); (m), dichotomized at the median (Hscore bmedian: negative; Hscore Nmedian:
Table 8
Overall patient survival and tumor-speciﬁc survival
Parameter Overall survival Tumor-speciﬁc survival
Total n Events n Mean 95% CI P Events n Mean 95% CI P
Patient no. 1255 154 156.2 ± 2.5 151.4-161.1 24 183.3 ± 1.4 180.6-186.0
Age group .001 .152
b66 y 624 66 162.0 ± 3.0 156.1-167.9 17 181.1 ± 1.9 177.2-185.0
≥66 y 631 88 149.3 ± 4.0 141.4-157.1 7 186.3 ± 1.3 183.7-188.8
T category .181 b.001
T2a 156 22 155.6 ± 6.3 143.3-167.9 1 187.6 ± 1.5 184.7-190.5
T2b 88 13 140.9 ± 5.1 130.9-150.9 1 160.1 ± 1.9 156.5-163.7
T2c 561 52 157.7 ± 4.9 148.0-167.3 4 186.7 ± 1.2 184.2-189.1
T3a 250 33 157.7 ± 4.6 148.6-166.8 8 179.5 ± 3.2 173.2-185.8
T3b 180 29 144.8 ± 7.2 130.8-158.9 9 175.2 ± 5.0 165.4-185.1
T4 16 3 147.6 ± 18.0 112.3-182.9 1 170.6 ± 0.0 170.6-170.6
N category .004 .009
N0 1077 122 158.6 ± 2.6 153.5-163.7 19 183.6 ± 1.5 180.7-186.5
N1 128 19 125.6 ± 8.9 108.1-143.1 5 162.8 ± 4.8 153.3-172.3
UICC stage .087 b.001
I 142 20 155.9 ± 6.6 143.0-168.8 0 nc nc
II 631 62 161.1 ± 3.6 154.1-168.1 5 186.9 ± 0.9 184.9-188.8
III 330 47 157.3 ± 4.1 149.2-165.3 13 179.2 ± 2.9 173.6-184.8
IV 140 21 130.1 ± 7.9 114.6-145.6 6 162.4 ± 4.5 153.7-171.2
Lymphatic invasion .257 .197
L0 789 63 143.4 ± 2.4 138.6-148.1 8 158.8 ± 1.2 156.4-161.2
L1 83 9 109.3 ± 5.3 99.0-119.7 2 123.1 ± 2.4 118.4-127.8
Venous invasion .003 .015
V0 888 70 144.4 ± 2.16 140.1-148.6 10 158.9 ± 1.1 156.7-160.9
V1 15 4 77.2 ± 9.2 59.2-95.2 1 91.1 ± 7.0 77.3-104.8
Perineural invasion .951 .439
Pn0 65 4 102.1 ± 3.2 95.8-108.4 0 nc nc
Pn1 453 44 153.3 ± 3.3 146.8-159.9 9 168.9 ± 2.5 164.1-173.8
Resection status .238 .001
R0 945 110 157.4 ± 2.9 151.7-162.9 11 185.9 ± 0.9 183.9-187.8
R1 270 39 153.2 ± 5.0 143.3-163.1 12 176.2 ± 3.7 168.9-183.5
R2 1 0 nc nc 0 nc nc
GS .005 b.001
6 416 43 157.0 ± 5.2 146.9-167.1 1 187.9 ± 0.6 186.7-189.1
7 (3 + 4) 420 48 159.6 ± 3.9 151.9-167.2 7 184.7 ± 1.7 181.4-188.1
7 (4 + 3) 180 22 154.9 ± 6.7 141.7-168.1 2 181.2 ± 4.8 171.8-190.5
8 120 28 139.2 ± 7.3 124.8-153.6 10 168.5 ± 5.8 157.2-179.9
9 101 10 158.6 ± 9.6 139.7-177.4 3 179.7 ± 5.6 168.8-190.7
10 6 3 31.0 ± 6.1 19.1-42.9 1 36.9 ± 6.4 24.2-49.5
Integrin expression
αvβ5 basal + 501 45 162.8 ± 3.8 155.4-170.2 .149 3 186.9 ± 1.2 184.7-189.3 .037
αvβ5 cytoplasmatic + 718 77 155.5 ± 3.6 148.6-162.5 .728 13 181.2 ± 2.3 176.6-185.8 .971
αvβ5 membranous + 165 33 146.0 ± 5.8 134.6-157.5 .012 5 180.9 ± 3.7 173.6-188.2 .211
αv-pan basal + 472 47 160.5 ± 4.2 152.2-168.8 .852 3 187.7 ± 1.1 185.6-189.8 .050
αv-pan cytoplasmatic + 535 59 155.8 ± 3.9 148.1-163.5 .984 9 181.9 ± 2.5 177.1-186.8 .465
αv membranous + 510 46 161.3 ± 4.1 153.3-169.3 .473 7 183.9 ± 2.3 179.5-188.3 .996
Survival is denoted in months. “+” denotes positive status, parameter divided by the median. nc denotes not calculated.
349K. Heß et al. / Annals of Diagnostic Pathology 18 (2014) 343–350speciﬁc death lead to the speculation of a potential prognosticmarker in
the course of pharmacologic therapy.
Two general methodical issues need to be considered. Only 24
patients died of prostate cancer, and a mean follow-up period of
70 months is too short to capture the time of death of the whole co-
hort. However, the small number of tumor-speciﬁc deaths is similar
to other clinical studies with a median observation period of 10
years [34]. The comprehension of biochemical cancer recurrence,
instead of or in addition to death from prostate cancer, is another
important surrogate end point. Unfortunately, the postoperative
serum prostate-speciﬁc antigen levels were unavailable for this
study, and only tumor-speciﬁc survival could be considered as an
end point.
Integrin expression is heterogeneous in tumor cells, regardless of the
different GPs. Strong staining can exist in close vicinity toweak staining.
The expression depends on the individual growth pattern of the pros-
tate cancer itself. This putatively limits the value of TMAs, which carry
the risk of a sampling error by harboring a GP which is not representa-
tive for the entire tumor and may need further consideration of future
investigations on integrins in prostate cancer.Funding
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